

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 29 Apr 2020 14:18:44 +0000  
**To:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** RE: two things

Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Billet, Courtney (NIH/NIAID) [E] (b) (6)  
**Sent:** Wednesday, April 29, 2020 9:16 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)  
**Subject:** ASF: two things

Talked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had in there about an EUA. Our release has been updated (attached) with the sentence highlighted below.

ALSO: Bill Hall called me to ask if you had alerted the Secretary to this (so the press release clearance process isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you wish to now?

As part of the U.S. Food and Drug Administration's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate.